CELC · Celcuity Inc.

Track CELC — free

$72.10 -3.03 (-4.03%) At close · Oct 2

Russell 2000 member Rebalance outlook locked

Market Cap

$3.96B

48.93M

Volume · Oct 2 1.42M Avg daily vol (3M) 1.17M

Up next

Latest filing: 10-Q

filed Aug 13, 2026

Q2 2026 earnings call transcript

call held Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$226.48M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-4.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+25.5%

Year over year · more shares

Price change (1Y)

+45.9%

Trailing year

Short interest

23.2%

Latest settlement · 12.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −31%

below

Price vs 50-day avg −17%

below

RSI (14) 30

neutral

MACD trend Negative

52-week position 26%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −25%

trailing

6-month return −40%

trailing

YTD return −28%

this year

Relative strength −52%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $87 › 200d $104 — 200d above 50d

Institutional flow Distributing

1 of 278 funds reported for Sep 30 · net -115 sh shares

Insider flow Distributing

Net -$317.8M over 90 days · 100% sells

Short interest Rising

23.22% of float · ▲ +6.3% MoM · 12.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

278 holders — near 3-yr high, broad support

Squeeze score 70

high risk · 0–100

Fundamentals

Weak

EPS growth −34%

Y/Y

Free cash flow $-153.5M

Balance sheet $28.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 74%

annualized · 1-yr

Max drawdown −50%

past year

ATR 6.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−31% Bearish

Price vs 50-day avg

−17% Bearish

RSI (14)

30 Neutral

MACD trend

Negative Bearish

52-week position

26% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $87 › 200d $104 — 200d above 50d

Institutional flow Distributing

1 of 278 funds reported for Sep 30 · net -115 sh shares

Insider flow Distributing

Net -$317.8M over 90 days · 100% sells

Short interest Rising

23.22% of float · ▲ +6.3% MoM · 12.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

278 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $46 Now $72 · 26% Range high $145

vs 200-day avg -31% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash, cash equivalents and short-term investments	$754M	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CELC Celcuity Inc. this stock	$3.96B	-27.7%	—	—	23.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

278

% held: 119.5%
Reported: 1 of 278
Top holder: BAKER BROS. ADVISORS LP

Held Float

View

Held by Funds

Fund positions

260

View

Short & Settlement

Short Interest Rising

Shares short

11.4M

Days to cover: 12.5d
Change: +672.2K sh

View

Short Volume

Short vol %

30%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

31.6K

Value: $2.8M
As of: Sep 10, 2026

View

Off-Exchange

Off-exchange %

47.7%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$317.8M

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Tom Malinowski

Amount: $1.0K–$15.0K
Traded: May 26, 2021

View

Financials

Net income (FY)

$-177.0M

EPS diluted: $-3.79

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 2, 2026
This year: 24

View

Proposed Sales

Value

$291.0M

Shares: 2.8M
Filed: Jul 14, 2026

View

Exempt Offerings

Offering

$352.7M

Filed: Sep 23, 2025

View

Earnings & Events

Webcasts

Last webcast

Sep 8, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CELC	-9.3%	-25.2%	-40.1%	-9.3%	-27.7%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-9.1%	-24.8%	-52.3%	-10.3%	-40.6%

Key facts CIK 1603454 CUSIP 15102K100 13F (30d) 5 filings 5 filers Visit website Investor relations

CELC · Celcuity Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance